Biolexis Therapeutics has achieved a transformative milestone in metabolic drug discovery with the successful resolution of ...

WALKING into the WeightWatchers meeting with her mum, then-eight-year-old Sarah Le Brocq was wide-eyed. It was 1990 and she ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

Transformational drugs rarely emerge from a targeted, application-driven approach. Rather, they arise from deep scientific inquiry over many years, an approach that only robust, early-stage funding ...

LOS ANGELES, CA, USA I March 03, 2025 I Laekna (2105.HK) announced that the U.S. Food and Drug Administration (FDA) has approved the IND for LAE120, an ...

The news has been littered with stories these days about people losing weight using GLP-1 weight loss drugs like Ozempic. Now ...

ABSTRACT: Obesity has become a global chronic metabolic disease, posing a serious threat to public health. Glucagon-like peptide-1 (GLP-1) is an important hormone secreted by the L cells of the small ...

Credit: MPE “If you look at the distribution of the galaxy clusters in the sky in a spherical shell with a distance of 416 to 826 million light-years, you immediately notice a huge structure that ...

With the rising global obesity epidemic and the increasing demand for effective weight-loss treatments, the biopharma industry faces mounting pressure to revolutionize GLP-1 manufacturing to meet ...

In older adults with diabetes, GLP-1 receptor agonists were tied to a slightly lower risk for depression compared with one diabetes drug class but not another, a target emulation trial using Medicare ...

I will be particularly interested in the company’s plan to attract and retain weight loss subscribers in the coming absence of popular GLP-1 compounds.

This indicates that GLP-1 receptor agonists lead to greater reduction in overall body fat than that in muscle mass, resulting in an overall body fat percentage decrease of around 4.5%.